|
Accueil > Actualité
AstraZeneca: starts phase 1/2 study for ovarian cancer
(CercleFinance.com) - AstraZeneca and US partner Aravive on Tuesday said that they have begun Phase 1/2 clinical trial of a treatment for patients with platinum-resistant recurrent epithelial ovarian cancer.
The investigator-sponsored trial, meaning that the sponsor is not a commercial entity, but rather a clinical investigator, will focus on the combination of AstraZeneca's durvalumab and Aravive's AVB-500. The clinical trial - which is recruiting patients - is jointly funded by Aravive and AstraZeneca. Copyright (c) 2019 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
